Editorial board disclosure policy

(Last updated December 2022)
All editors responsible for recommending or making publication decisions are requested to disclose on an annual basis any potential conflict of interest, including current or recent financial relationships with any commercial entity whose products or services may be contained in the journal content.
The following competing interests were disclosed:
Dr Michael Bryer-Ash
Dr Bryer-Ash holds shares in Dexcom Inc, a maker of continuous glucose sensors, and is also a minor shareholder in Pfizer Pharmaceuticals Inc. Effective June 2019, he will also be an unpaid Member of the Governing Board of Iowa Tribe of Kansas’ Tribal Health System; a small Native American tribal health system in the state of Kansas, USA, serving exclusively Native American patients.
Dr Daniel Chen
Dr Chen has received personal fees from Besin and Inova and also non-financial support from Amgen.
Associate Professor Roger Chen
Associate Professor Roger Chen has received speaker’s fees from MSD, Astra Zeneca, Eli Lily, Sanofi, Boehringer Ingelheim and Novo Nordisk. He is also an Editorial Board member of Clinical Management Issues, Endocrinology Today and an Issue Editor for Frontiers in Endocrinology.
Dr Georgios K Dimitriadis
Dr Dimitriadis has received research grants from NovoNordisk UK Research Foundation, Association for the Study of Obesity (ASO), Bayer and The Jon Moulton Foundation. He has also received honoraria and support to set up educational events from NovoNordisk, Consilient Health, Medtronic, J&J/Ethicon and Napp Pharmaceuticals. NovoNordisk has provided drugs and placebo compounds for investigator-initiated research projects using their agents. Ipsen and NovoNordisk have provided travel expenses and participation in medical conferences. Dr Dimitriadis is a reviewer and editor for Frontiers in Endocrinology.
Dr Marie Freel
Dr Freel has received fees for serving on the Advisory Board for Diurnal Pharmaceuticals (June 2021). She has also received sponsorship from Novo Nordisk to attend The Endocrine Society’s annual meeting 2022.
Dr Julia Galhardo
Dr Galhardo is principal investigator in two Novo Nordisk trials, Scale Kids and Pioneer Teens. She has received speaker's fees for lectures about diabetes from Sanofi, Lilly and Menarini, and meetings expenses from Abbott, Sanofi and Menarini. She is a review editor in Paediatric Endocrinology for Frontiers.
Dr Warrick Inder
Dr Inder is on the advisory board of Pfizer and has received speaker honoraria from Amgen.
Professor Paul Kaplowitz
Professor Kaplowitz was paid for participation in an advisory board meeting for the liquid l-thyroxine preparation Tirosint and was also paid for his role as head of the DSMB for a Tolmar study.
Professor Christian Koch
Professor Koch receives a royalty honorarium for the textbook Endocrine Hypertension published by Springer, and an Honorarium for the Associate Editorship of Journal of Clinical and Translational Endocrinology. He is also on the Editorial Board of Journal of the Endocrine Society.
Dr Fabienne Langlois
Dr Langlois currently works as a consultant for Novartis.
Dr Gefsi Mintziori
Dr Mintziori has received payment for teaching in the postgraduate programme 'Medical Research Methodology' at the Aristotle University of Thessaloniki Medical School.
Dr Christopher Muir
Dr Muir is supported by a National Health and Medical Research Council (NHMRC) postgraduate scholarship.
Professor Rodis D Paparodis
Professor Paparodis has received honoraria/consultation fees from the following pharmaceutical companies: Merck Co, Amgen, Astra Zeneca, Boehringer Ingelheim, RAFARM, ITF Pharma, Libytec, Intermed and Abbott. He is an Editorial Board Member for Frontiers in Reproductive Medicine, International Journal of Diabetes and Endocrinology and Reproductive Epidemiology.
Professor Luca Persani
Professor Persani received fees for consulting from Sandoz and Merck-Serono and also travel fees from Sanofi.
Professor Paraskevi Xekouki
Professor Xekouki has research funding from Novartis and Ipsen pharmateuticals, and is a medical advisor to Τakeda, Boehringer Ingelheim, Novartis/Sandoz and Ipsen.
Dr Andromachi Vryonidou
Dr Vryonidou has received fees for lectures and multicenter studies from Novo Nordisk, Pharmaserv Lilly and Boehringer Ingelheim.
The following editors reported no competing interests:
  • Dr Priyanka Bakhtiani
  • Dr Marco Bonomi
  • Professor Isabelle Bourdeau
  • Dr Sarantis Livadas
  • Dr Sofia Llahana
  • Professor Ayrton Moreira
  • Dr Katerina Saltiki
Bioscientifica staff and freelancers working on the journal reported no conflicts of interest. Article authors' declarations are stated in each journal article. Referees must disclose any competing interests before agreeing to review any submission. For more information please refer to our ethical guidelines.
This policy follows the recommendations of the International Committee of Medical Journals Editors (ICMJE) and the Committee on Publication Ethics (COPE).